View this video message from Benjamin Movsas, MD, FASTRO, Chairman, ASTRO Scientific Program Committee:
- A phase III randomized clinical trial comparing conventional RT (3-D CRT) vs. image-guided IMRT for reducing late bowel toxicity in cervical cancer.
- A randomized clinical trial comparing involved field irradiation (IFI) vs. elective nodal irradiation (ENI) for locally-advanced thoracic esophageal squamous cell carcinoma.
- A phase II Children’s Oncology Group study examining the role of conformal radiation therapy for pediatric patients with localized ependymoma.
- A study on the comparison of radiomics features and SUV in predicting the outcome for cervical cancer treatment.
- A study looking at the quality of life outcomes of the ASCENDE-RT trial, a randomized clinical trial of RT for prostate cancer.
- A prospective phase II trial looking at deintensified chemoradiation therapy for low risk HPV-associated oropharyngeal squamous cell carcinoma.
- A NRG/RTOG analysis for locally advanced non-small cell lung cancer, comparing 3-D CRT vs. IMRT.
- A study assessing the response and biomarkers for radiation and immune checkpoint blockade.
Please note that late-breaking abstracts may be added to the Plenary and Clinical Trials sessions.
Other important scientific sessions include:
- Best of Physics Session featuring abstracts with high quality, innovative science that have an important impact for radiation oncology clinical practice.
- The biology track with studies utilizing novel technologies to study the underlying radiobiology of tumors and develop novel radiation therapeutic strategies.
- Plus, more than 1,600 paper posters and 19 ePoster sessions with 171 abstracts, covering all the major disease sites
The early-bird registration deadline is Thursday, July 30, so REGISTER NOW to take advantage of the lowest rates.
Visit the Annual Meeting website for more information.